In this regard, we previously demonstrated that anti-CCR7 antibodies and different chemical inhibitors of the signaling pathways activated by CCR7 efficiently blocked in vitro migration of primary CLL cells in response to the CCR7 ligands. This evidence concerns the gene CCR7 and B-cell chronic lymphocytic leukemia.